Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.77 |
| ▸ | LMNA | P02545 | 6/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.59 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28952954 | 0.87 | SMN1; SMN2 (0.75) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9891806 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9891812 | 0.85 | ADORA3 (0.74) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9892965 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL4243345 | 0.74 | ADORA3 (1.00) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9852151 | 0.70 | SMN1; SMN2 (0.75) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16254958 | 0.70 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9852174 | 0.69 | ADORA3 (0.77) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL4241185 | 0.69 | ADORA3 (1.00) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9891818 | 0.68 | NPC1 (0.52) | SMN1; SMN2LMNANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SMN1; SMN2 4659/4885LMNA 4696/4885NPC1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.